In one study [10], the patients received SCT at first establishment of CR status or later, depending on the patient’s age and availability of a suitable donor, but no differences were found in incidence of SCT in first CR, OS, EFS, time interval for relapse according to the mutation status of KIT. Another study [17] found SCT to improve outcome of relapse or refractory CBF-AML, but the mutation status of KIT was not considered, which was also reported by Zhu et al [48]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.